Search

Your search keyword '"Le Naour, Julie"' showing total 3 results
Start Over Author "Le Naour, Julie" Topic immunogenic cell death Language english
3 results on '"Le Naour, Julie"'

1. FLT3LG - a biomarker reflecting clinical responses to the immunogenic cell death inducer oxaliplatin.

Author

Pol JG, Le Naour J, and Kroemer G

Subjects
Biomarkers, Tumor, Humans, Membrane Proteins, Antineoplastic Agents pharmacology, Colorectal Neoplasms drug therapy, Colorectal Neoplasms immunology, Colorectal Neoplasms pathology, Immunogenic Cell Death, Liver Neoplasms drug therapy, Liver Neoplasms immunology, Liver Neoplasms secondary, Oxaliplatin pharmacology
Abstract

The fms-related tyrosine kinase 3 (FLT3) ligand (FLT3LG) binds to FLT3 on dendritic cells to stimulate their differentiation and expansion, hence facilitating tumor antigen cross-presentation and anticancer immune responses. A recent study by Abrahamsson et al. demonstrates that, in patients receiving a hepatic arterial infusion of oxaliplatin for the treatment of colorectal cancer metastases, an increase in circulating FLT3LG predicts long-term survival of those individuals whose metastases have been rendered resectable. Thus, FLT3LG constitutes a potential biomarker of immune activation by immunogenic cell death-inducing chemotherapeutics such as oxaliplatin. Abbreviations : DC, dendritic cell; FLT3, fms-related tyrosine kinase 3; FLT3LG, FLT3 ligand; ICI, immune checkpoint inhibitor; OXA, oxaliplatin., (© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.)

Published
2020
Full Text
View/download PDF

2. A loss-of-function polymorphism in ATG16L1 compromises therapeutic outcome in head and neck carcinoma patients.

Author

Le Naour, Julie, Sztupinszki, Zsofia, Carbonnier, Vincent, Casiraghi, Odile, Marty, Virginie, Galluzzi, Lorenzo, Szallasi, Zoltan, Kroemer, Guido, and Vacchelli, Erika

Subjects
*CROHN'S disease, *PATTERN perception receptors, *HEAD & neck cancer, *SINGLE nucleotide polymorphisms, *CELL morphology, *SQUAMOUS cell carcinoma
Abstract

The anticancer immune response is shaped by immunogenic cell stress and death pathways. Thus, cancer cells can release danger-associated molecular patterns that act on pattern recognition receptors expressed by dendritic cells and their precursors to elicit an antitumor immune response. Here, we investigated the impact of single nucleotide polymorphisms (SNPs) in genes affecting this cancer-immunity dialogue in the context of head and neck squamous cell carcinoma (HNSCC). We observed that homozygosity for a loss-of-function SNP (rs2241880, leading to the substitution of a threonine residue in position 300 by an alanine) affecting autophagy related 16 like 1 (ATG16L1) is coupled to poor progression-free survival in platinum-treated HNSCC patients. This result was obtained on a cohort of patients enrolled at the Gustave Roussy Cancer Campus and was validated on an independent cohort of The Cancer Genome Atlas (TCGA). Homozygosity in rs2241880 is well known to predispose to Crohn's disease, and epidemiological associations between Crohn's disease and HNSCC have been reported at the levels of cancer incidence and prognosis. We speculate that rs2241880 might be partially responsible for this association. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

3. Trial Watch: experimental TLR7/TLR8 agonists for oncological indications.

Author

Frega, Giorgio, Wu, Qi, Le Naour, Julie, Vacchelli, Erika, Galluzzi, Lorenzo, Kroemer, Guido, and Kepp, Oliver

Subjects
GENITAL warts, TYPE I interferons, ACTINIC keratosis, TOLL-like receptors, ANTINEOPLASTIC agents
Abstract

Resiquimod (R848) and motolimod (VTX-2337) are second-generation experimental derivatives of imiquimod, an imidazoquinoline with immunostimulatory properties originally approved by the US Food and Drug Administration for the topical treatment of actinic keratosis and genital warts more than 20 years ago. Both resiquimod and motolimod operate as agonists of Toll-like receptor 7 (TLR7) and/or TLR8, in thus far delivering adjuvant-like signals to antigen-presenting cells (APCs). In line with such an activity, these compounds are currently investigated as immunostimulatory agents for the treatment of various malignancies, especially in combination with peptide-based, dendritic cell-based, cancer cell lysate-based, or DNA-based vaccines. Here, we summarize preclinical and clinical evidence recently collected to support the development of resiquimod and motolimod and other TLR7/TLR8 agonists as anticancer agents. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results